Sage Journals: Discover world-class research

Free access

Letter

First published 2011-1

Therapeutic Effectiveness of Minimal Doses of Rituximab in a Patient with Rheumatoid Arthritis

V. Bruzzese

International Journal of Immunopathology and Pharmacology

Retricted access

Letter

First published 2012-3

Maximally tolerated versus minimally effective dose: the case of rituximab in multiple sclerosis

A Scott Nielsen, Augusto Miravalle, Annette Langer-Gould [...]

Multiple Sclerosis Journal

Open access

Review article

First published 2022

Rituximab Dosing in Glomerular Diseases: A Scoping Review

Husam Alzayer, Kuruvilla K. Sebastian, Michelle M. O’Shaughnessy

Canadian Journal of Kidney Health and Disease

Retricted access

Research article

First published 2009-02

A Simple and Safe Method for 131 I Radiolabeling of Rituximab for Myeloablative High-Dose Radioimmunotherapy

Ly Tran, Joke W. Baars, Harry J. Maessen [...]

Cancer Biotherapy and Radiopharmaceuticals

Open access

Research article

First published 2019

Repeated low-dose rituximab treatment based on the assessment of circulating B cells in patients with refractory myasthenia gravis

Kyomin Choi, Yoon-Ho Hong, So-Hyun Ahn [...]

Therapeutic Advances in Neurological Disorders

Retricted access

Review article

First published 2022-11

Extended dosing of monoclonal antibodies in multiple sclerosis

Zoé LE van Kempen, Alyssa A Toorop, Finn Sellebjerg [...]

Multiple Sclerosis Journal

Open access

Research article

First published 2010

Rituximab for Multirelapsing,Steroid-Dependent or Steroid-Resistant,Minimal-Change Nephropathy – a Report of Nine Adult Cases

Annette Bruchfeld, Samiha Benedek, Marie Hilderman [...]

Nephrology Research & Reviews

Retricted access

Case report

First published 2022-9

Gefitinib induced Pemphigus Vulgaris with PRIDE complex

Raushan Kumar Chaudhary, Ramesh Bhandari, Bhavana Doshi [...]

Journal of Oncology Pharmacy Practice

Open access

Case report

First published 2017-1

Long-Term Response and Possible Cure of Patients With B-Cell Malignancies With Dose-Escalated Rituximab

Lauren M. Jacobs, Peter H. Wiernik, Janice P. Dutcher [...]

Journal of Investigative Medicine High Impact Case Reports

Open access

Research article

First published 2017

Anti-CD20 Cell Therapies in Multiple Sclerosis—A Fixed Dosing Schedule for Ocrelizumab is Overkill

Jagannadha Avasarala

Drug Target Insights

Search results